SYRS — Syros Pharmaceuticals, Inc.

Summary of Syros Pharmaceuticals Q3 2024 Earnings Call

1. Key Financial Results and Metrics

• Revenue: No revenue recognized in Q3 2024, down from $3.8 million in Q3 2023 due to the termination of the collaboration agreement with Pfizer.
• R&D Expenses: $20.5 million in Q3 2024, a decrease from $28.3 million in Q3 2023, attributed to reduced external R&D costs and headcount.
• G&A Expenses: $5.7 million in Q3 2024, down from $7.8 million in Q3 2023, also due to headcount reductions and lower consulting expenses.
• Net Loss: $6.4 million, or $0.16 per share, compared to a net loss of $40.1 million, or $1.43 per share, in the same period last year.
• Cash Position: $58.3 million as of September 30, 2024, down from $79 million as of June 30, 2024. The company believes this will fund operations into Q3 2025.

2. Strategic Updates and Business Highlights

• Tamibarotene Development: The company is focused on advancing tamibarotene as a new treatment for higher-risk MDS patients with RARA gene overexpression. The pivotal SELECT-MDS-1 Phase 3 trial is nearing data readout, expected in mid-November 2024.
• Market Opportunity: Syros estimates a market opportunity of approximately $1.6 billion for higher-risk MDS therapeutics in the U.S., with tamibarotene targeting over $800 million for patients with RARA overexpression.
• Commercial Preparation: The company is preparing for the potential launch of tamibarotene, focusing on market awareness, education on RARA biology, and ensuring manufacturing capabilities are in place.

3. Forward Guidance and Outlook

• Upcoming Data Release: Key data from the SELECT-MDS-1 trial will be disclosed in mid-November, focusing on the primary endpoint of complete response (CR) rates and safety profile.
• NDA Filing: Following the data release, the company plans to file for New Drug Application (NDA) approval, contingent on the successful validation of trial data.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The complete absence of revenue in Q3 2024 raises concerns about financial sustainability, especially following the loss of the Pfizer collaboration.
• Cash Burn: Although the company has sufficient cash to fund operations into Q3 2025, the declining cash position could pose risks if the upcoming trial data does not meet expectations or if further funding is needed.
• Regulatory Risks: The success of the upcoming trial data is critical, and any failure to meet primary endpoints could significantly impact the company’s future prospects.

5. Notable Q&A Insights

• Efficacy Benchmarks: Management discussed the historical complete response rates for azacitidine, which serve as a benchmark for evaluating tamibarotene's performance in the SELECT-MDS-1 trial.
• Safety Profile: Emphasis was placed on the importance of a favorable safety profile, especially for elderly patients with comorbidities, which could enhance tamibarotene's acceptance in the medical community.
• Commercial Strategy Post-Data: The company is actively working on commercial strategies to ensure broad access to tamibarotene, including educational initiatives and infrastructure development.
• Future of 5609: The CDK7 inhibitor 5609 remains a valuable asset, with management exploring business development opportunities for its potential.

Overall, Syros Pharmaceuticals is at a pivotal moment with the upcoming trial data that could significantly influence its future trajectory, both commercially and financially.